Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sofosbuvir + daclatasvir (Shinpoong Pharma)
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sofosbuvir + daclatasvir is a combination of two direct-acting antiviral (DAA) agents originally developed for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir is a nucleotide analog that inhibits the HCV NS5B RNA-directed RNA polymerase, while daclatasvir inhibits the HCV non-structural protein 5A (NS5A). For COVID-19, this combination was repurposed by Shin Poong Pharmaceutical Co. Ltd. and evaluated in a Phase 2 clinical trial for symptomatic outpatients with mild disease. The rationale for its use against SARS-CoV-2 is based on evidence suggesting that these DAAs may have activity against the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), thereby potentially inhibiting viral replication.
- Other names
- sofosbuvir/daclatasvir
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on sofosbuvir + daclatasvir (Shinpoong Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sofosbuvir + daclatasvir (Shinpoong Pharma).